The Vanguard Group Discloses Position in Oxford Biomedica

The Vanguard Group, Inc. has released a Form 8.3 disclosure regarding its interests in the securities of Oxford Biomedica plc. The disclosure indicates that Vanguard holds a position of 1,215,134 ordinary shares, constituting 1.01% of the total shares of Oxford Biomedica. This disclosure is mandated by Rule 8.3 of the Takeover Code, as Vanguard holds more than 1% of the relevant securities.

The date of the position held is noted as January 14, 2026. The form does not mention any additional parties to the offer or any dealings aside from the disclosed position. Furthermore, there are no cash-settled or stock-settled derivative positions, nor are there any indemnity or option agreements associated with these securities. A Supplemental Form 8 was not attached to this disclosure.